Triethylenetetramine and metabolites: Levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients

Drug Metabolism and Disposition

Volumn 35, Issue 2, 2007, Pages 221-227

  Lu, Jun ^a   Chan, Yi Kai ^a   Gamble, Gregory D ^b   Poppitt, Sally D ^b   Othman, Asma A ^a   Cooper, Garth J S ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; DRUG METABOLITE; N1 ACETYLTRIETHYLENETETRAMINE; N1,N10 DIACETYLTRIETHYLENETETRAMINE; TRIENTINE; UNCLASSIFIED DRUG; ZINC;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; HEART FAILURE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; CHELATING AGENTS; COPPER; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MIDDLE AGED; TRIETHYLENETETRAMINE; ZINC;

EID: 33846403733     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012922     Document Type: Article

References (19)

1. Arinc E, Arslan S, and Adali O (2005) Differential effects of diabetes on CYP2E1 and CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit liver. Arch Toxicol 79:427-433.
2. Cooper GJ, Chan YK, Dissanayake AM, Leahy FE, Keogh GF, Frampton CM, Gamble GD, Brunton DH, Baker JR, and Poppitt SD (2005) Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 54:1468-1476.
3. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, Saafi L, Dissanayake AM, Cowan BR, Young AA, et al. (2004) Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53:2501-2508.
4. Gibbs KR and Walshe JM (1986) The metabolism of trientine: animal studies, in Orphan Diseases and Orphan Drugs (Scheinberg IH and Walshe JM eds) pp 33-42, Manchester University Press in Association with the Fulbright Commission, Manchester, UK.
5. Gu K, Cowie CC, and Harris MI (1998) Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21:1138-1145.
6. Kobayashi M, Sugawara M, Saitoh H, Iseki K, and Miyazaki K (1990) [Intestinal absorption and urinary excretion of triethylenetetramine for Wilson's disease in rat]. Yakugaku Zasshi 110:759-763.
7. Kodama H, Meguro Y, Tsunakawa A, Nakazato Y, Abe T, and Murakita H (1993) Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson's disease. Tohoku J Exp Med 169:59-66.
8. Kodama H, Murata Y, Iitsuka T, and Abe T (1997) Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci 61:899-907.
9. Leggio L, Addolorato G, Abenavoli L, and Gasbarrini G (2005) Wilson's disease: clinical, genetic and pharmacological findings. Int J Immunopathol Pharmacol 18:7-14.
10. Nakano Y, Nohta H, Yoshida H, Saita T, Fujito H, Mori M, and Yamaguchi M (2002) Liquid chromatographic determination of triethylenetetramine in human and rabbit sera based on intramolecular excimer-forming fluorescence derivatization. J Chromatogr B 774:165-172.
11. Sheweita SA, Newairy AA, Mansour HA, and Yousef MI (2002) Effect of some hypoglycemic herbs on the activity of phase I and II drug-metabolizing enzymes in alloxan-induced diabetic rats. Toxicology 174:131-139.
12. Struthers AD and Morris AD (2002) Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359:1430-1432.
13. Takeda S, Ono E, Matsuzaki Y, Wakui Y, Ono H, Kushida H, Takizawa Y, Kaneko M, Takeda S, Wakamatsu T, et al. (1995a) [Metabolic fate of triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250) 3. Bioavailability of TJA-250 in rats after single administration]. Oyo Yakuri 49:179-186.
14. Takeda S, Ono E, Wakui Y, Matsuzaki Y, Ishihara K, Yanagisawa E, Takeda S, and Wakamatsu T (1995b) [Metabolic fate of triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250) 2. Metabolism study in rats using 14C-TJA-250]. Oyo Yakuri 49:173-178.
15. 14C-TJA-250]. Oyo Yakuri 49:163-171.
16. Tanabe R (1996) Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilson's disease. Hokkaido J Med Sci 71:217-228.
17. Walshe JM (1982) Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1:643-647.
18. Wang Z, Hall SD, Maya JF, Li L, Asghar A, and Gorski JC (2003) Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85.
19. Wormhoudt LW, Commandeur JNM, and Vermeulen NPE (1999) Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-Transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59-124.